Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetic (PK) of GDC-0349 administered once daily (QD), orally (PO).
Epistemonikos ID: 8acf0df6dc369ba8ac4dfaa53050c401300815bd
First added on: May 06, 2024